Ilaris
® (
canakinumab) is a prescription medication approved to treat rare genetic autoinflammatory conditions known as cryopyrin-associated periodic syndromes (CAPS), such as familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). It belongs to a group of medicines known as monoclonal antibodies.
Who Makes This Medication?
Ilaris is manufactured by Novartis Pharma Stein AG for Novartis Pharmaceuticals Corporation.
Ilaris is a manufactured antibody (a protein normally produced by the immune system). It works by blocking the actions of interleukin-1 beta (IL-1β), a protein that causes inflammation in the body. People with CAPS have increased levels of IL-1β. By blocking its action, Ilaris reduces the inflammation and symptoms associated with CAPS.
In a clinical study, Ilaris was shown to reduce symptoms of CAPS. In the study, 97 percent of people had minimal symptoms or improved symptoms after eight weeks of treatment. No one in the study experienced a flare-up of symptoms over eight months of treatment.